



#### Keith C. Ferdinand, MD, FAHA

Gerald S. Berenson Endowed Chair in Preventative
Cardiology
Professor of Medicine
John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA

#### Debbie Cohen, MD

Professor of Medicine
Director of Hypertension Programs
University of Pennsylvania
Philadelphia, PA





## Agenda

Overcoming Barriers to Hypertension Control and Cardiovascular Disease:
 We Need to Do Better – Dr. Ferdinand

 Resistant Hypertension: Definitions, Current Treatment and Emerging Approaches – Dr. Cohen





Keith C. Ferdinand, MD,FAHA
Gerald S. Berenson Endowed Chair in Preventative Cardiology
Professor of Medicine
John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA



## **Disclosures**

Speaker's Bureau- None

Consultant- Amgen, Novartis, Lilly, Medtronic, Janssen


Stocks- None

Patents- None

18TH ANNUAL



## Goals






Discuss uncontrolled HTN as a major driver of CV mortality gap and suboptimal outcomes in Blacks vs. Whites


Highlight the importance of assessing and addressing social determinants of health in hypertension



## Association between Intensity of BP Reduction and Relative Treatment Effects for Prevention of Major CV Events



## **SPRINT Long Term Follow-up**



## Mortality rates by Cardiovascular Disease




Chart 14-3. Deaths attributable to cardiovascular disease (CVD), United States, 1900 to 2018.

CVD (International Classification of Diseases, 10th Revision codes I00–I99) does not include congenital heart disease. Before 1933, data are for a death registration area, not the entire United States.

Source: Unpublished National Heart, Lung, and Blood Institute tabulation using National Vital Statistics System.<sup>36</sup>



## ESRD: Racial differences in prevalence USRD, 2019

**US African American Population US ESRD Population** 13.6% 31.6%




## The U.S. Has the Lowest Life Expectancy Among Large, Wealthy Countries While Far Outspending Them on Health Care

Life expectancy (2021) and per capita healthcare spending (2021 or nearest year)

Country	Life expectancy	Health spending, per capita
United States	76.1	\$12,318
United Kingdom	80.8	\$5,387
Germany	80.9	\$7,383
Austria	81.3	\$6,693
Netherlands	81.5	\$6,190
Belgium	81.9	\$5,274
Comparable Country Average	82.4	\$6,003
France	82.5	\$5,468
: Sweden	83.2	\$6,262
Australia	83.4	\$5,627
Switzerland	84.0	\$7,179
• Japan	84.5	\$4,666  Peterson-KFF Health System Tracker






Note: Starting with 2018 data, race is presented as single-race estimates (only one race was reported on the death certificate). Data on life expectancy by racial groups is provisional for 2021.

KFF health system tracker

## **CENTRAL ILLUSTRATION:** Impact of Social Determinants of Health on Health Through Health Care Providers and Systems



Brandt EJ, et al. J Am Coll Cardiol. 2023;81(14):1368-1385.



### **Annals of Internal Medicine**

## Original Research

# Social, Behavioral, and Metabolic Risk Factors and Racial Disparities in Cardiovascular Disease Mortality in U.S. Adults


#### **An Observational Study**

Jiang He, MD, PhD; Joshua D. Bundy, MPH, PhD; Siyi Geng, MS; Ling Tian, MS; Hua He, PhD; Xingyan Li, MSPH; Keith C. Ferdinand, MD; Amanda H. Anderson, MPH, PhD; Kirsten S. Dorans, ScD; Ramachandran S. Vasan, MD; Katherine T. Mills, MSPH, PhD; and Jing Chen, MD, MSc

**Conclusion:** The Black-White difference in CVD mortality diminished after adjustment for behavioral and metabolic risk factors and completely dissipated with adjustment for social determinants of health in the U.S. population.



## HR of Black–White difference CVD mortality, adjusted for metabolic, behavioral, and social risk factors, in U.S. adults aged ≥20 y.






### Mean Prevalence of Cardiometabolic Health Indicators: Redlining


- (A) Cardiometabolic health according to HOLC grade.
- (B) Cardiometabolic health risk factors to HOLC grade.
- A ("best" or green),
- B ("still desirable" or blue),
- C ("definitely declining" or yellow), and
- D ("hazardous" or red).


- HOLC =Home Owners' Loan Corporation.
- 1935- Federal Home Loan Bank Board tasked Home Owners' Loan Corporation: determine U.S. "residential security" mark up maps (239 cities)



### How 'redlining' shaped New Orleans neighborhoods—is it too late to be fixed

- Green "Type A" neighborhoods "safe" suburbs
- Yellow "Type C" neighborhood "declining" areas/riskier investments
- Red "Type D" neighborhood (largely Black, poor, working class) "hazardous" for "infiltration of inharmonious racial or nationality groups."





## The Southern Diet: REGARDS Study (N=6,897)

- High Southern diet intake: largest mediator of HTN difference Black vs. White individuals for both men and women.
- Fried foods, organ meats, processed meats, eggs/egg dishes, added fats, high-fat dairy foods, sugar-sweetened beverages, and bread.
- Other research, associated increased risk of incident stroke, CHD, ESRD, CKD, sepsis, cancer mortality, and cognitive decline.





#### Weighing Factors That Impact Higher ASCVD Risk in Black Adults


#### **Factors to Maximize**

#### 1. SDOH

- Adverse environments
- · Inadequate health access
- Low SES
- Limited educational attainment
- Food desserts
- · Structural inequities
- · Intrinsic bias


#### 2. Uncontrolled major risk factors

- HTN
- Obesity (especially Black females)
- T2DM
- Smoking
- Physical inactivity
- Suboptimal LDL goal attainment and statin intensity
- 3. CAC scoring with intermediate risk score
- 4. Elevated Lp(a)



#### **Factors to Minimize**

- 1. Skin color or self-identified race
- 2. Unmeasured genetic factors
- 3. Low HDL-C as increased risk
- 4. High HDL-C and low triglycerides as indicating lower risk



JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

© 2022 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION
PUBLISHED BY ELSEVIER

VOL. 80, NO. 22, 2022


**EDITORIAL COMMENT** 

## HDL-C in Black Adults for ASCVD Risk Calculation



Benefit or Barrier to Achieving Health Equity?\*

Keith C. Ferdinand, MD



Tsao, C. et al Circulation. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association,

#### Hypertension


Volume 79, Issue 9, September 2022; Pages 1981-1983



#### **EDITORIAL**

Hypertension Control Among US Adults, 2009 to 2012 Through 2017 to 2020, and the Impact of COVID-19

HTN control changes: NHANES and 3 health plans- Commercial, Medicaid, and Medicare



Brent M. Egan. Hypertension. 79(9).



## Who is Uncontrolled vs Controlled? Subgroup analyses for BP control

- BP control less:
- N-H Black vs. N-H white adults (aPR = 0.88; 95% CI, 0.81-0.96).
- Age <45 yrs. or >75 yrs.
  - BP control more likely:
  - Private insurance vs. without (aPR = 1.4; 95% CI, 1.08-1.8);
  - Medicare vs. without (aPR = 1.47; 95% CI, 1.15-1.89);
- Usual health care facility vs. without (aPR = 1.48; 95% CI, 1.13-1.94);
- Health care visit in past yr. vs. without (aPR = 5.23; 95% CI, 2.88-9.49).



## Implementation of HBP Guidelines: We Must Do Better

- → NHLBI clinical practice guidelines (CPGs) 1970s
- → Joint National Committees(JNC) of the National High Blood Pressure Program(NHBEP)
- → The uneven implementation of evidence-based CPGs is widely recognized as a continuing challenge to improving public health



## REVIEW

### **Annals of Internal Medicine**

# Comparative Effectiveness of Implementation Strategies for Blood Pressure Control in Hypertensive Patients

A Systematic Review and Meta-analysis

Katherine T. Mills, PhD; Katherine M. Obst, MS; Wei Shen, MS; Sandra Molina, MPH; Hui-Jie Zhang, MD, PhD; Hua He, PhD; Lisa A. Cooper, MD, MPH; and Jiang He, MD, PhD

121 comparisons 100 articles n= 55,920

Ann Intern Med. 2018;168:110-120.



## Mean net reduction in BP with implementation strategies

Implementation Strategy	Net Change in BP (95% Cl), <i>mm Hg</i>	Studies, <i>n</i>	
Systolic BP	I	(95 % CI), IIIII Hg	
Team-based care with titration by nonphysicia	an <del>-</del>	-7.1 (-8.9 to -5.2)	10
Team-based care with titration by physician	-	-6.2 (-8.1 to -4.2)	19
Multilevel strategy without team-based care		-5.0 (-8.0 to -2.0)	8
Health coaching	-	-3.9 (-5.4 to -2.3)	38
Electronic decision-support systems	-	-3.7 (-5.2 to -2.2)	4
Home BP monitoring	-	-2.7 (-3.6 to -1.7)	26
Provider training	=	-1.4 (-3.6 to 0.7)	5
Audit and feedback	-	-0.8 (-2.1 to 0.5)	2
	-15 0	15	

Net Change in BP, mm Hg



## Clinical Practice Guideline

## 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Hypertension. 2018;71:e13-e115



### **2017 HBP Guideline :First Step Combination**

COR	LOE	Recommendations for Race and Ethnicity
	C-LD	Two or more anti-HTN medications are recommended to achieve a BP target of less than 130/80 mm Hg in most adults with HTN, especially in black adults with HTN.

Black adults with hypertension (without HF or CKD), initial antihypertensive treatment should include a thiazide diuretic or CCB



#### 2017 HBP Guideline Strategies to Improve HTN Treatment and Control

- Adherence strategies
  - Once daily dosing
  - Combination pills
- Strategies to promote lifestyle modification
- Team-based care
  - Health professionals: physicians, nurses, pharmacists
  - Patient
  - Staff: office staff and community health workers
  - Others: spouse, relatives, friends
- Use EHR and Patient Registries
- Telehealth strategies
- Performance measures and Quality Improvement initiatives
- Financial incentives



### **AHA Scientific Statement**


## Resistant Hypertension: Detection, Evaluation, and Management A Scientific Statement From the American Heart Association

Robert M. Carey, MD, FAHA, Chair; David A. Calhoun, MD, FAHA, Vice Chair;
George L. Bakris, MD, FAHA; Robert D. Brook, MD, FAHA; Stacie L. Daugherty, MD, MSPH;
Cheryl R. Dennison-Himmelfarb, PhD, MSN, FAHA; Brent M. Egan, MD;
John M. Flack, MD, MPH, FAHA; Samuel S. Gidding, MD, FAHA; Eric Judd, MD, MS;
Daniel T. Lackland, DrPH, FAHA; Cheryl L. Laffer, MD, PhD, FAHA;
Christopher Newton-Cheh, MD, MPH, FAHA; Steven M. Smith, PharmD, MPH, BCPS;
Sandra J. Taler, MD, FAHA; Stephen C. Textor, MD, FAHA; Tanya N. Turan, MD, FAHA;
William B. White, MD, FAHA; on behalf of the American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council

Hypertension. 2018;72:e53-e90



## Why Patients Have Resistant HTN?





# Lifestyle modification continues cornerstone of antihypertensive therapy

Exclude other causes of hypertension, including

secondary causes, white-

coat effect and medication

nonadherence

Management of Resistant Hypertension Step 1

## Ensure low sodium diet (<2400 mg/d)

#### Maximize lifestyle interventions:

- ≥6 hours uninterrupted sleep
- Overall dietary pattern
- Weight loss
- Exercise

Optimize 3-drug regimen

Ensure adherence to 3
antihypertensive agents
of different classes
(RAS blocker, CCB,
diuretic) at maximum or
maximally tolerated
doses. Diuretic type must
be appropriate for kidney
function.

BP not at target



Step 2

Substitute optimally dosed thiazide-like diuretic: chlorthalidone or indapamide\* for the prior diuretic.

BP not at target



Step 3



Add mineralocorticoid receptor antagonist (MRA): spironolactone or eplerenone\*\*

## N=1776 65.9% female

## Resistant Hypertension

# Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension JHS and the REGARDS Study

Aisha T. Langford, Oluwasegun P. Akinyelure, Tony L. Moore Jr,
George Howard, Yuan-I Min, William B. Hillegass, Adam P. Bress, Gabriel S. Tajeu, Mark Butler,
Byron C. Jaeger, Yuichiro Yano, Daichi Shimbo, Gbenga Ogedegbe, David Calhoun,
John N. Booth III, Paul Muntner

Langford AT, Akinyelure OP, Moore TL, et al. Hypertension. 2020;76(5):1600-1607. doi:10.1161/hypertensionaha.120.14836




Black Adults
With
Apparent
TreatmentResistant
Hypertension

Langford, A. Clinical implications. *Hypertension*. 2020;76(5):1331-1331.

**Evidence-Based Lifestyle Factors and Recommended** Pharmacological Treatment are Underutilized in Black Adults with Apparent Treatment-Resistant Hypertension (aTRH) had 4 ideal lifestyle factors taking chlorthalidone or indapamide Ŗ taking spironolactone 9.8% or eplerenone had 3 ideal 14.5% lifestyle factors **Jackson Heart Study and REasons for Geographic** And Racial Differences in Stroke Study

participants with aTRH



Perm J 2016 Winter;20(1):53-59 http://dx.doi.org/ 10.7812/TPP/15-052

**BP GOALS** Treat adults with confirmed hypertension to a goal BP < 140/90 mm Hg. In adults with ASCVD, CKD, age ≥ 75 years, or 10-year ASCVD risk<sup>3</sup> ≥ 10%, consider treating to a goal SBP < 130 (Exclude adults with eGFR<20 from this lower target.) mm Hg. Thiazide Diuretic<sup>2</sup> ACE Inhibitor 1/ Thiazide Diuretic Management If ACEI intolerant or HCTZ 25 mg ⇒ 50 mg pregnancy potential of Adult 20/25 mg X 1/2 daily Lisinopril / HCTZ 20/25 mg X 1 daily Blood Chlorthalidone 12.5 mg ⇒ 25 mg (advanced as needed) 20/25 mg X 2 daily Pressure Pregnancy potential: avoid ACE inhibitors1 If not in control (BP) KP **CLINICAL** For ACEI intolerance due to cough, use ARB2 **PRACTICE** Add losartan 25 mg daily ⇒ 50 mg daily ⇒ 100 mg daily **GUIDELINES** Do not combine ACEI and ARB. **NATL** If not in control Pregnancy potential: avoid ARBs1 **FEBRUARY** Calcium Channel Blocker (CCB) 2019 Add amlodipine 2.5 mg daily ⇒ 5 mg daily ⇒ 10 mg daily If not in control Spironolactone\* - Aldosterone Receptor Antagonist (ARA) Spironolactone 12.5 mg ⇒ 25 mg daily \*If on thiazide AND eGFR ≥ 60 mL/min/1.73 m² AND potassium < 4.5 mmol/L If spironolactone eligibility criteria not met: bisoprolol 2.5 mg ⇒ 5 mg daily ⇒ 10 mg daily

Titrate to BP; maintain pulse of > 55

https://kpcmi.org/files/blood-pressure-clinician-guide-kpcmi.pdf

## Hypertension medication treatment protocol<sup>1</sup>

For adults without CHF, CAD, pregnancy, CKD stage 3 or albuminuria ≥ 300 mg/d or ≥ 300 mg/g albumin-to-creatinine ratio\*



Check labs at clinician's discretion.

#### Not on antihypertensive medication

- Prescribe dihydropyridine CCB plus ACEI or ARB in a single-pill combination (SPC).<sup>1a,2,3</sup>
- If concerned about hypotension, frailty in the very old, increased risk of medication intolerance or other factors, consider a low dose SPC or monotherapy with a CCB.<sup>1a,1b</sup>

#### Already on antihypertensive medication

 Prescribe one additional medication from a different class (ACEI or ARB, CCB, or thiazide or thiazide-like diuretic) preferably as a single-pill combination (SPC), if available.<sup>1a</sup>

If CCB not tolerated (e.g., edema), consider replacing with thiazide-like diuretic. 

If diabetes with albuminuria and monotherapy desired, use an ACEI or ARB. 

a

Reassess BP in 2-4 weeks<sup>1c</sup>

Use self-measured BP (SMBP) if available.1c

https://www.ama-assn.org/system/files/2020-11/hypertension-medication-treatment-protocol.pdf

# 15 minutes

The designated time for the routine clinic visit in not adequate to control conditions which are chronic, ongoing and 80% affected by the SDOH



### 2017 ACC/AHA HBP Guideline Out-of-Office and Self-Monitoring of BP

COR	LOE	Recommendation for Out-of-Office and Self- Monitoring of BP		
	A <sup>SR</sup>	Out-of-office BP measurements are recommended confirm the diagnosis of hypertension and titration of BP-lowering medication, in conjunction with telehealth counseling or clinical interventions.  SR indicates systematic review.		





# THE HEALTHY HEART COMMUNITY PREVENTION PROJECT: A MODEL FOR PRIMARY CARDIOVASCULAR RISK REDUCTION IN THE AFRICANAMERICAN POPULATION

Keith C. Ferdinand, MD, FACC New Orleans, Louisiana J Natl Med Assoc. 1995;87(8 Suppl):638-641

The Healthy Heart Community Prevention Project (HHCPP) was initially conceived as a 1-year pilot program funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). Although the NHLBI funding has expired, the program is being maintained by volunteer coordinators.

The Healthy Heart Community Prevention Project is an outgrowth of the National Medical Association's (NMA) Healthy People 2000 Program, whose mandate is to provide accessible health education and screening

the local physicians but also has community support from various professional, voluntary health, and community organizations (Table 1). Thus, by having developed a strong coalition, the HHCPP has been able to sustain a massive health screening and intervention project.

In an effort to highlight the significance of both the heart and the home in the African-American community, the HHCPP chose a logo that incorporates the two. Furthermore, the project's slogan is "You've got to







Contents lists available at ScienceDirect

#### American Heart Journal Plus: Cardiology Research and Practice

journal homepage: www.sciencedirect.com/journal/ american-heart-journal-plus-cardiology-research-and-practice



Research paper

TEXT MY BP MEDS NOLA: A pilot study of text-messaging and social support to increase hypertension medication adherence<sup>★</sup>

Daphne P. Ferdinand <sup>a</sup>, Tina K. Reddy <sup>b</sup>, Madeline R. Wegener <sup>b</sup>, Pavan S. Guduri <sup>b</sup>, John J. Lefante <sup>c</sup>, Saihariharan Nedunchezhian <sup>b</sup>, Keith C. Ferdinand <sup>b,\*</sup>



<sup>&</sup>lt;sup>a</sup> Healthy Heart Community Prevention Project (HHCPP), New Orleans, LA, United States of America

<sup>&</sup>lt;sup>b</sup> Tulane University School of Medicine, New Orleans, LA, United States of America

<sup>&</sup>lt;sup>c</sup> Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States of America

#### **Text My BP NOLA**




Fig. 2. Change in baseline and follow-up SBP and DBP.

American Heart Journal Plus: Cardiology Research and Practice 26 (2023) 100253



#### TULANE UNIVERSITY TRANSLATIONAL SCIENCE INSTITUTE (TUTSI)

# Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health (CHERISH)

Jiang He, MD, PhD, Primary Investigator
Thomas LaVeist, PhD, Co-Investigator
Keith Ferdinand, MD, FACC, FAHA, FASPC, FNLA, Co-Investigator
Marcia Ory, PhD, Co-Investigator
Jing Chen, MD, MMSc, MSc, Co-Investigator
Lydia Bazzano, MD, PhD, MPH, Co-Investigator
Jeanette Gustat, PhD, MPH, Co-Investigator
Katherine Mills, MSPH, PhD, Co-Investigator
Hua He, PhD, Co-Investigator
Lizheng Shi, PhD, Co-Investigator
Caryn Bell, PhD, Co-Investigator

#### ORIGINAL ARTICLE

Los Angeles Barbershop Blood Pressure Study (LABBPS)

#### A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops



Ronald G. Victor, M.D., Kathleen Lynch, Pharm.D., Ning Li, Ph.D., Ciantel Blyler, Pharm.D., Eric Muhammad, B.A., Joel Handler, M.D., Jeffrey Brettler, M.D., Mohamad Rashid, M.B., Ch.B., Brent Hsu, B.S., Davontae Foxx-Drew, B.A., Norma Moy, B.A., Anthony E. Reid, M.D., and Robert M. Elashoff, Ph.D.




#### **BP Reduction in LA Black Barbershops**

Table 2. Primary and Secondary Blood-Pressure Outcomes.*							
Outcome	Intervention Group (N=132)	Control Group (N=171)	Intervention Effect	P Value†			
Blood pressure							
Systolic blood pressure — mm Hgt							
At baseline	152.8±10.3	154.6±12.0					
At 6 mo	125.8±11.0	145.4±15.2					
Change	-27.0±13.7	-9.3±16.0	–21.6 (–28.4 to –14.7)§	<0.001			
Diastolic blood pressure — mm Hg							
At baseline	92.2±11.5	89.8±11.2					
At 6 mo	74.7±8.3	85.5±12.0					
Change	-17.5±11.0	-4.3±11.8	-14.9 (-19.6 to -10.3)§	<0.001			
Hypertension control at 6 mo — no. (%)							
Blood pressure <140/90 mm Hg	118 (89.4)	55 (32.2)	3.4 (2.5 to 4.6)¶	<0.001			
Blood pressure <135/85 mm Hg	109 (82.6)	32 (18.7)	5.5 (2.6 to 11.7)¶	<0.001			
Blood pressure <130/80 mm Hg	84 (63.6)	20 (11.7)	5.7 (2.5 to 12.8)¶	<0.001			

Victor RG, et al. N Engl J Med. 2018;378(14):1291-1301.

#### Positive components of the LABBP intervention



#### Three Legs on the Stool to Achieve BP Control

- Achieving Million Hearts BP goal by 2022 simultaneously
- 78.1% BP U.S. overall HTN control

Circulation: Cardiovascular Quality and Outcomes


#### ORIGINAL ARTICLE

### Clinic-Based Strategies to Reach United States Million Hearts 2022 Blood Pressure Control Goals

**A Simulation Study** 

**BACKGROUND:** The Centers for Disease Control and Prevention's Million Hearts initiative includes an ambitious ≥80% blood pressure control goal in US adults with hypertension by 2022. We used the validated Blood Pressure Control Model to quantify changes in clinic-based hypertension

Brandon K. Bellows, PharmD, MS Natalia Ruiz-Negrón, PharmD



Bellows, B. Et al Circ Cardiovasc Qual Outcomes. 2019;12:e005624



#### Journal of the American Heart Association


#### **CONTEMPORARY REVIEW**

## Locking the Revolving Door: Racial Disparities in Cardiovascular Disease

Gladys Velarde , MD; Katia Bravo-Jaimes , MD; Eric J. Brandt , MD, MHS; Daniel Wang, MD; Paul Douglass , MD; Luis R. Castellanos, MD, MPH; Fatima Rodriguez , MD, MPH; Latha Palaniappan, MD, MS; Uzoma Ibebuogu, MD; Rachel Bond , MD; Keith Ferdinand, MD; Gina Lundberg , MD; Ritu Thamman , MD; Krishnaswami Vijayaraghavan, MD; Karol Watson , MD, PhD

J Am Heart Assoc. 2023;12:e025271. DOI: 10.1161/JAHA.122.025271















#### **Hypertension**

Hypertension. 2023;80:e00-e00.

#### **AHA/AMA SCIENTIFIC STATEMENT**

Implementation Strategies to Improve Blood Pressure Control in the United States: A Scientific Statement From the American Heart Association and American Medical Association

Marwah Abdalla, MD, MPH, Vice Chair; Shari D. Bolen, MD, MPH; Jeffrey Brettler, MD; Brent M. Egan, MD; Keith C. Ferdinand, MD; Cassandra D. Ford, PhD; Daniel T. Lackland, DrPH; Hilary K. Wall, MPH; Daichi Shimbo, MD, Chair; on behalf of the American Heart Association and American Medical Association



- →Antiracism efforts Adverse SDOH mitigated through partnership with underrepresented racial/ethnic groups or historically excluded communities
- →Paired with multilevel strategies that support wider adoption of evidence-based interventions for BP control

Hypertension. 2023;80:e00-e00



- Accurate BP measurement and increased use of SMBP-educate and train clinicians and patients to select validated BP devices and measure BP accurately
- Create robust, integrated, and scalable health information technology infrastructure for efficiently relaying SMBP data to the care team and communicating treatment plan back to the patients




- → Team-based care —disseminate and sustain advanced practice professionals, nurses, pharmacists, care managers, and community health workers
- → Lifestyle modification strategies individual and system-level strategies reduce sodium in food, increase access to healthy food, and ensure safe areas for physical exercise

Hypertension. 2023;80:e00-e00



- →Standardized treatment protocols using team-based care
- Once-daily, low-cost, effective BP meds and single-dose combination pill regimens
- Optimize medication acceptance and adherence
- → Ask patients their preferences about anti-HTN medications
- → Wider implementation continuous QI with clear, timedefined, standardized metrics coupled with reminders and regular feedback to clinicians and practices





#### **Steps to Eliminating HTN Disparities: Current and Emerging Interventions** Improve BP, medication adherence, and healthcare utilization Promote<sup>1</sup> **SMBP** Use of intensive **GDMT Use Combination** Therapy Healthy eating (i.e. DASH diet, low sodium), increase physical activity, reduce stress Improve TLC SES position, race/ethnicity, access to care, residential environment

Address SDOH

#### **Reaching Health Equity**

- Targeted interventions are needed to identify and eliminate disparities, based on race/ethnicity, sex/gender, geography, socioeconomic status, ability or disability
- Health equity is a moral and practical imperative





## Thank you!

Keith C. Ferdinand MD, FACC, FAHA, FASPC, FNLA <u>kferdina@tulane.edu</u>

Twitter: @kcferdmd

